KAI Pharmaceuticals
http://www.kaipharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From KAI Pharmaceuticals
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
AbbVie Stays On Script With Michael As Next CEO
As previously indicated, AbbVie will go with an internal candidate, president and COO Robert Michael, to succeed Richard Gonzalez as CEO. The company has recently positioned Michael prominently.
Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1
Public Company Edition: Fourth quarter 2023 fundraising fell 25.1% from Q4 2022, including a 24.2% drop in follow-on dollars, but recent activity has been robust, including $300m and $350m offerings by 4DMT and Autolus. Also, BMS sold $13bn in notes to fund Karuna and RayzeBio deals.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice